Gossamer Bio Company Insiders
GOSS Stock | USD 1.70 0.01 0.58% |
Slightly above 55% of Gossamer Bio's corporate insiders are selling. The analysis of the overall insider sentiment regarding Gossamer Bio suggests that many insiders are impartial. Gossamer Bio employs about 144 people. The company is managed by 18 executives with a total tenure of roughly 21 years, averaging almost 1.0 years of service per executive, having 8.0 employees per reported executive.
Faheem Hasnain Chairman Executive Chairman of the Board, Co-Founder |
Christian Waage President Executive Vice President General Counsel |
Insider Sentiment 45
Impartial
Selling | Buying |
Latest Trades
2024-06-24 | Richard Aranda | Disposed 1908 @ 0.66 | View | ||
2024-06-21 | Faheem Hasnain | Acquired 372000 @ 0.67 | View | ||
2024-03-27 | Faheem Hasnain | Disposed 23172 @ 1.16 | View | ||
2024-03-18 | Richard Aranda | Disposed 4018 @ 1.33 | View | ||
2023-11-13 | Bryan Giraudo | Acquired 200000 @ 0.56 | View | ||
2023-06-22 | Richard Aranda | Disposed 1814 @ 1.29 | View | ||
2023-04-04 | Bryan Giraudo | Acquired 55000 @ 1.02 | View | ||
2023-03-22 | Faheem Hasnain | Acquired 440500 @ 1.14 | View | ||
2023-03-20 | Faheem Hasnain | Acquired 168683 @ 1.03 | View | ||
2023-03-16 | Laura Carter | Disposed 6029 @ 1.1 | View | ||
2022-10-24 | Laura Carter | Disposed 4876 @ 12.07 | View |
Monitoring Gossamer Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gossamer Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Gossamer Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.1268) % which means that it has lost $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.0057) %, meaning that it created substantial loss on money invested by shareholders. Gossamer Bio's management efficiency ratios could be used to measure how well Gossamer Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.19 in 2025. Return On Capital Employed is likely to gain to -0.21 in 2025. Non Current Assets Total is likely to gain to about 9.2 M in 2025, whereas Total Assets are likely to drop slightly above 299.4 M in 2025.Common Stock Shares Outstanding is likely to gain to about 237.5 M in 2025, whereas Net Loss is likely to drop (216.8 M) in 2025.
Gossamer Bio Workforce Comparison
Gossamer Bio is rated # 4 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 884. Gossamer Bio retains roughly 144 in number of employees claiming about 16% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.41) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.72. Gossamer Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gossamer Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gossamer Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Gossamer Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gossamer Bio Notable Stakeholders
A Gossamer Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gossamer Bio often face trade-offs trying to please all of them. Gossamer Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gossamer Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Faheem Hasnain | Executive Chairman of the Board, Co-Founder | Profile | |
Christian Waage | Executive Vice President General Counsel | Profile | |
Deanna Weber | Vice President of Human Resources | Profile | |
Bryan Giraudo | COO CFO | Profile | |
Colin Rowlings | Senior CMC | Profile | |
Robert Smith | Chief Officer | Profile | |
Matt Cravets | Senior Biometrics | Profile | |
Jeff Boerneke | General Secretary | Profile | |
Louis Cherico | Senior Treasury | Profile | |
Richard MD | Chief Officer | Profile | |
Mario Orlando | Senior Planning | Profile | |
Caryn Peterson | Executive Affairs | Profile | |
Laura Carter | Chief Officer | Profile | |
Jeanine Anthony | Senior Marketing | Profile | |
Kelly Dawson | Senior Lead | Profile | |
Robert Roscigno | Senior Disease | Profile | |
Christian JD | Executive Administration | Profile | |
Lisa Nolan | MD Ireland | Profile |
About Gossamer Bio Management Performance
The success or failure of an entity such as Gossamer Bio often depends on how effective the management is. Gossamer Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gossamer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gossamer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.18) | (0.19) | |
Return On Capital Employed | (0.22) | (0.21) | |
Return On Assets | (0.18) | (0.19) | |
Return On Equity | (1.92) | (2.01) |
Please note, the imprecision that can be found in Gossamer Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gossamer Bio. Check Gossamer Bio's Beneish M Score to see the likelihood of Gossamer Bio's management manipulating its earnings.
Gossamer Bio Workforce Analysis
Traditionally, organizations such as Gossamer Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gossamer Bio within its industry.Gossamer Bio Manpower Efficiency
Return on Gossamer Bio Manpower
Revenue Per Employee | 796.5K | |
Revenue Per Executive | 6.4M | |
Net Loss Per Employee | 392.6K | |
Net Loss Per Executive | 3.1M | |
Working Capital Per Employee | 1.8M | |
Working Capital Per Executive | 14.7M |
Additional Tools for Gossamer Stock Analysis
When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.